Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
My previous session
Most popular
  Report  
Delayed Quote. Delayed Nyse - 03/20 04:00:16 pm
49.19 USD   -0.83%
03/20BRISTOL MYERS SQUIBB : Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Correction to Bristol-Myers Squibb Overheard Article
DJ
03/19If This Is Failure, Show Me Success -- Overheard
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/14/2019 03/15/2019 03/18/2019 03/19/2019 03/20/2019 Date
49.89(c) 49.96(c) 49.86(c) 49.6(c) 49.19(c) Last
31 496 053 27 370 738 11 628 247 11 656 536 17 438 167 Volume
-2.12% +0.14% -0.20% -0.52% -0.83% Change
More quotes
Financials (USD)
Sales 2019 23 977 M
EBIT 2019 6 878 M
Net income 2019 6 782 M
Finance 2019 3 655 M
Yield 2019 3,33%
Sales 2020 25 104 M
EBIT 2020 7 275 M
Net income 2020 6 766 M
Finance 2020 7 163 M
Yield 2020 3,42%
P/E ratio 2019 9,41
P/E ratio 2020 11,77
EV / Sales2019 3,20x
EV / Sales2020 2,91x
Capitalization 80 311 M
More Financials
Company
Bristol-Myers Squibb Company specializes in the development, manufacturing and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - cancers (33.5%); - cardiovascular diseases (23.5%); - viral diseases (19.8%); - immune diseases (11.9%); - psychiatric... 
Sector
Pharmaceuticals
Calendar
04/04Ex-dividend day for
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
03/20BRISTOL MYERS SQUIBB : Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Correction to Bristol-Myers Squibb Overheard Article
DJ
03/19If This Is Failure, Show Me Success -- Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Starboard Issues Investor Presentation Opposing Bristol-M..
PR
03/19BRISTOL MYERS SQUIBB : Files Investor Presentation Highlighting Significant Bene..
BU
03/18BRISTOL MYERS SQUIBB : Additional Proxy Soliciting Materials - Non-Management (d..
PU
03/18BRISTOL MYERS SQUIBB : Filing of certain prospectuses and communications in conn..
PU
03/15BRISTOL MYERS SQUIBB : Proxy Statment - Contested Solicitations (definitive)
PU
03/15BRISTOL MYERS SQUIBB : Mutual funds start to put their mouth where their money i..
RE
03/14Citi dealmaker says mergers and acquisitions to slow down
RE
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPA
More recommendations
Sector news : Pharmaceuticals - NEC
08:45aEISAI : Biogen scraps Alzheimer's trial, shares skid
RE
06:32aRoche Sues U.S. Executives Over Diabetes Test Strips -Reuters
DJ
03:09aERNESTO BERTARELLI : French healthcare group Stallergenes to be bought out by Be..
RE
02:48aBAYER : Cancer Verdict Pummels Bayer
DJ
02:48aPFIZER : Adds to Streak of Deals in Gene Therapies
DJ
More sector news : Pharmaceuticals - NEC
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 57,0 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-4.58%80 311
JOHNSON & JOHNSON6.39%365 572
NOVARTIS10.52%237 139
PFIZER-3.39%234 120
ROCHE HOLDING LTD.11.28%234 082
MERCK AND COMPANY7.42%211 867